BG108553A - Кристали, включващи сол на ябълчената киселина c n-[2-(диетиламино) етил]-5-[(5-флуоро-2-оксо-3н-индол-3-илиден) метил]-2,4-диметил-1н-пирол-3-карбоксамид, методи за получаването им и техни състави - Google Patents
Кристали, включващи сол на ябълчената киселина c n-[2-(диетиламино) етил]-5-[(5-флуоро-2-оксо-3н-индол-3-илиден) метил]-2,4-диметил-1н-пирол-3-карбоксамид, методи за получаването им и техни състави Download PDFInfo
- Publication number
- BG108553A BG108553A BG108553A BG10855304A BG108553A BG 108553 A BG108553 A BG 108553A BG 108553 A BG108553 A BG 108553A BG 10855304 A BG10855304 A BG 10855304A BG 108553 A BG108553 A BG 108553A
- Authority
- BG
- Bulgaria
- Prior art keywords
- crystal
- malic acid
- diethylamino
- pyrrole
- ethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31235301P | 2001-08-15 | 2001-08-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
BG108553A true BG108553A (bg) | 2005-04-30 |
Family
ID=23211067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG108553A BG108553A (bg) | 2001-08-15 | 2004-01-29 | Кристали, включващи сол на ябълчената киселина c n-[2-(диетиламино) етил]-5-[(5-флуоро-2-оксо-3н-индол-3-илиден) метил]-2,4-диметил-1н-пирол-3-карбоксамид, методи за получаването им и техни състави |
Country Status (43)
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3168218B1 (en) | 2001-08-15 | 2018-11-14 | Pharmacia & Upjohn Company LLC | A crystal comprising an l-malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide for use as a medicament |
HN2003000272A (es) * | 2002-09-10 | 2008-07-29 | Pharmacia Italia Spa | Formulaciones que comprenden un compuesto de indolinona |
SI1670785T1 (sl) * | 2003-10-02 | 2010-10-29 | Pharmacia & Upjohn Co Llc | Soli in polimorfi spojine indolinona, substituirani s pirolom |
US20060009510A1 (en) * | 2004-07-09 | 2006-01-12 | Pharmacia & Upjohn Company Llc | Method of synthesizing indolinone compounds |
DE602005023474D1 (en) * | 2004-07-22 | 2010-10-21 | Lilly Co Eli | Kristallines variables hydrat von (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridincarbonsäureamid-hemisuccinatsalz |
MX2007014087A (es) * | 2005-05-12 | 2008-02-07 | Pfizer | Combinaciones y procedimientos para usar un compuesto de indolinona. |
KR101050906B1 (ko) | 2005-09-19 | 2011-07-20 | 화이자 프로덕츠 인크. | 피롤 치환된 2-인돌리논의 고체 염 형태 |
US20090004213A1 (en) | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
US20100256392A1 (en) * | 2007-11-21 | 2010-10-07 | Teva Pharmaceutical Industries Ltd. | Polymorphs of sunitinib base and processes for preparation thereof |
EP2220072A2 (en) | 2007-11-21 | 2010-08-25 | Teva Pharmaceutical Industries Ltd. | Polymorphs of sunitinib base and processes for preparation thereof |
US8389562B2 (en) * | 2007-12-12 | 2013-03-05 | Medichem, S.A. | Polymorphic forms of a 3-pyrrole substituted 2-indolinone |
EP2113248A1 (en) | 2008-04-29 | 2009-11-04 | Ratiopharm GmbH | Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide |
EP2090306A1 (en) | 2008-02-13 | 2009-08-19 | Ratiopharm GmbH | Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
AU2009215377A1 (en) * | 2008-02-21 | 2009-08-27 | Generics [Uk] Limited | Novel polymorphs and processes for their preparation |
EP2098521A1 (en) * | 2008-03-06 | 2009-09-09 | Ratiopharm GmbH | Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation |
WO2009124037A1 (en) * | 2008-03-31 | 2009-10-08 | Teva Pharmaceutical Industries Ltd. | Processes for preparing sunitinib and salts thereof |
EP2280960A1 (en) * | 2008-04-16 | 2011-02-09 | Natco Pharma Limited | Novel polymorphic forms of sunitinib base |
CA2725001C (en) * | 2008-05-23 | 2014-05-13 | Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd. | Dihydroindolone derivatives |
ES2392762T3 (es) * | 2008-06-13 | 2012-12-13 | Medichem, S.A. | Procedimiento para preparar una sal de malato de 2-indolinona sustituida con 3-pirrol |
EP2138167A1 (en) | 2008-06-24 | 2009-12-30 | ratiopharm GmbH | Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
WO2009156837A2 (en) * | 2008-06-26 | 2009-12-30 | Medichem, S.A. | Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt |
CA2730079A1 (en) | 2008-07-10 | 2010-01-14 | Generics [Uk] Limited | Processes for the preparation of crystalline forms of sunitinib malate |
WO2010010454A2 (en) | 2008-07-24 | 2010-01-28 | Medichem, S.A. | Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt |
US8618309B2 (en) | 2008-07-24 | 2013-12-31 | Teva Pharmaceutical Industries Ltd. | Sunitinib and salts thereof and their polymorphs |
JP2012500838A (ja) * | 2008-08-25 | 2012-01-12 | ジェネリクス・(ユーケー)・リミテッド | スニチニブの新規な多形およびその調製方法 |
AU2009286520A1 (en) * | 2008-08-25 | 2010-03-04 | Generics [Uk] Limited | Crystalline form of sunitinib and processes for its preparation |
AR073807A1 (es) * | 2008-10-10 | 2010-12-01 | Medichem Sa | Proceso para preparar el malato de sunitinib, sal de un acido mas debil que el malato como compuesto intermediario, y proceso para preparar dicha sal intermediaria. |
EP2181991A1 (en) | 2008-10-28 | 2010-05-05 | LEK Pharmaceuticals D.D. | Novel salts of sunitinib |
EP2186809A1 (en) | 2008-11-13 | 2010-05-19 | LEK Pharmaceuticals D.D. | New crystal form of sunitinib malate |
WO2010076805A2 (en) | 2009-01-02 | 2010-07-08 | Hetero Research Foundation | Novel polymorphs of sunitinib malate |
CA2995880C (en) | 2009-01-16 | 2021-01-05 | Exelixis, Inc. | Processes for preparing n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
EP2255792A1 (en) | 2009-05-20 | 2010-12-01 | Ratiopharm GmbH | Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide |
WO2011004200A1 (en) | 2009-07-10 | 2011-01-13 | Generics [Uk] Limited | Novel pyrrole derivatives |
WO2011033472A1 (en) | 2009-09-16 | 2011-03-24 | Ranbaxy Laboratories Limited | Salts of sunitinib |
US20120271056A1 (en) | 2009-11-12 | 2012-10-25 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline form i of l-malic acid salt of sunitinib |
US8916716B2 (en) | 2009-11-19 | 2014-12-23 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline form II of L-malic acid salt of sunitinib |
WO2011092664A1 (en) | 2010-01-29 | 2011-08-04 | Ranbaxy Laboratories Limited | Crystalline forms of l-malic acid salt of sunitinib |
WO2011100325A2 (en) | 2010-02-09 | 2011-08-18 | Sicor Inc. | Polymorphs of sunitinib salts |
WO2011104555A2 (en) | 2010-02-25 | 2011-09-01 | Generics [Uk] Limited | Novel process |
CA2792039A1 (en) | 2010-03-04 | 2011-09-09 | Ranbaxy Laboratories Limited | Process for the direct preparation of malic acid salt of sunitinib |
AU2011228765A1 (en) | 2010-03-18 | 2012-10-11 | Ranbaxy Laboratories Limited | Process for the preparation of malic acid salt of sunitinib |
WO2011128699A2 (en) | 2010-04-16 | 2011-10-20 | Generics [Uk] Limited | Novel process |
WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
DK2699598T3 (en) | 2011-04-19 | 2019-04-23 | Pfizer | COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER |
EP2828251B1 (en) | 2012-03-23 | 2018-10-31 | Laurus Labs Limited | An improved process for the preparation of sunitinib and its acid addition salts thereof |
PL399027A1 (pl) | 2012-04-27 | 2013-10-28 | Instytut Farmaceutyczny | Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu |
SG11201406592QA (en) | 2012-05-04 | 2014-11-27 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
US9604968B2 (en) | 2013-10-18 | 2017-03-28 | Sun Pharmaceutical Industries Limited | Pure crystalline Form II of L-malic acid salt of sunitinib and processes for its preparation |
US9278955B2 (en) | 2013-10-18 | 2016-03-08 | Sun Pharmaceutical Industries Limited | Ascorbic acid salt of sunitinib |
JP2016535989A (ja) | 2013-11-01 | 2016-11-24 | ファイザー・インク | 前立腺関連抗原を発現させるためのベクター |
CN104693187A (zh) * | 2013-12-10 | 2015-06-10 | 安杰世纪生物科技(北京)有限公司 | 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法 |
CN104744442B (zh) * | 2013-12-25 | 2019-05-28 | 江苏豪森药业集团有限公司 | 苹果酸舒尼替尼的制备方法 |
RU2567535C1 (ru) * | 2014-10-01 | 2015-11-10 | Олег Ростиславович Михайлов | КРИСТАЛЛИЧЕСКАЯ ε-МОДИФИКАЦИЯ N-[2-(ДИЭТИЛАМИНО)ЭТИЛ]-5-[(Z)-(5-ФТОР-1,2-ДИГИДРО-2-ОКСО-3Н-ИНДОЛ-3-ИЛИДЕН)МЕТИЛ]-2,4-ДИМЕТИЛ-1Н-ПИРРОЛ-3-КАРБОКСАМИД МАЛАТА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ |
CN105712979A (zh) * | 2014-12-05 | 2016-06-29 | 广州白云山医药集团股份有限公司白云山制药总厂 | 一种苹果酸舒尼替尼晶型ⅰ的制备方法 |
EP3539536A1 (en) | 2018-03-15 | 2019-09-18 | MH10 Spolka z ograniczona odpowiedzialnoscia | A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i |
WO2020216450A1 (en) | 2019-04-25 | 2020-10-29 | Synthon B.V. | Pharmaceutical composition comprising amorphous sunitinib |
SG11202111339WA (en) * | 2019-04-18 | 2021-11-29 | Meter Health Inc | Methods and compositions for treating respiratory arrhythmias |
KR20240025990A (ko) | 2022-08-19 | 2024-02-27 | 주식회사 스카이테라퓨틱스 | 무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUT64326A (en) | 1990-10-15 | 1993-12-28 | Pfizer | Process for production indole derivatives and pharmaceutical preparations containing these compounds |
IL100091A (en) | 1990-12-12 | 1998-08-16 | Zeneca Ltd | Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole) |
AU4337293A (en) | 1992-06-05 | 1994-01-04 | Merck Sharp & Dohme Limited | The sulphate salt of a substituted triazole, pharmaceutical compositions thereof, and their use in therapy |
DK0690864T3 (da) | 1993-03-12 | 2001-09-17 | Upjohn Co | Krystallinsk ceftiofur på fri syreform |
US5665878A (en) | 1994-08-31 | 1997-09-09 | Eli Lilly And Company | Stereoselective process for producing dihydro-2,3-benzodiazepine derivatives |
DE19503966C2 (de) | 1995-02-07 | 1998-07-02 | Mack Chem Pharm | Kristallmodifikation von 2,4-Diamino-6-hydroxymethylpteridin-Hydrobromid, Verfahren zu dessen Herstellung und dessen Verwendung |
US5597663A (en) * | 1995-05-30 | 1997-01-28 | Motorola, Inc. | Low temperature molten lithium salt electrolytes for electrochemical cells |
US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
US5673451A (en) * | 1995-07-06 | 1997-10-07 | Moore; James R. | Instructional toothbrush |
US20020045746A1 (en) | 1995-12-11 | 2002-04-18 | Barton Kathleen P. | Eplerenone crystalline form |
US20020038021A1 (en) | 1995-12-11 | 2002-03-28 | Barton Kathleen P. | Eplerenone crystalline form exhibiting enhanced dissolution rate |
US6066647A (en) | 1996-07-29 | 2000-05-23 | Pfizer Inc. | Zwitterionic forms of trovafloxacin |
EP1283203A1 (en) | 1996-08-14 | 2003-02-12 | G.D. Searle & Co. | Crystalline form of 4-(5-methyl-3-phenylisoxazol-4-yl) benzene-sulfonamide |
US6251355B1 (en) | 1996-12-25 | 2001-06-26 | Nippon Kayaku Kabushiki Kaisha | Fine cisplatin powder and process for the production thereof |
US5777185A (en) * | 1997-09-09 | 1998-07-07 | Laroche Industries Inc. | Production of organic fluorine compounds |
US6133305A (en) * | 1997-09-26 | 2000-10-17 | Sugen, Inc. | 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity |
US6012678A (en) * | 1998-01-26 | 2000-01-11 | The Boeing Company | Galley vacuum waste disposal system |
PT1956014T (pt) | 1998-06-19 | 2019-04-24 | Teijin Pharma Ltd | Polimorfos de ácido 2-(3-ciano-4-isobutiloxifenil)-4-metil- 5-tiazolecarboxílico e método para a sua produção |
PT1157019E (pt) * | 1998-12-17 | 2003-06-30 | Hoffmann La Roche | 4-alcenil (e alcinil) oxindolos como inibidores dequinases dependentes de ciclina em particular cdk2 |
US6239141B1 (en) * | 1999-06-04 | 2001-05-29 | Pfizer Inc. | Trovafloxacin oral suspensions |
ATE514676T1 (de) * | 1999-11-24 | 2011-07-15 | Sugen Inc | Ionisierbare indolinon derivate und deren verwendung als ptk liganden |
SK287142B6 (sk) | 2000-02-15 | 2010-01-07 | Sugen, Inc. | Inhibítory proteínkináz na báze pyrolom substituovaného 2-indolinónu, farmaceutický prípravok s ich obsahom a ich použitie |
US6316672B1 (en) | 2001-01-31 | 2001-11-13 | Grayson Walker Stowell | Form a of fluoxetine hydrochloride |
EP3168218B1 (en) | 2001-08-15 | 2018-11-14 | Pharmacia & Upjohn Company LLC | A crystal comprising an l-malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide for use as a medicament |
AU2009215377A1 (en) | 2008-02-21 | 2009-08-27 | Generics [Uk] Limited | Novel polymorphs and processes for their preparation |
WO2009156837A2 (en) | 2008-06-26 | 2009-12-30 | Medichem, S.A. | Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt |
-
2002
- 2002-08-13 EP EP16196036.4A patent/EP3168218B1/en not_active Expired - Lifetime
- 2002-08-13 ES ES02759342.5T patent/ES2453164T3/es not_active Expired - Lifetime
- 2002-08-13 SI SI200231093T patent/SI3168218T1/sl unknown
- 2002-08-13 AU AU2002324684A patent/AU2002324684B2/en not_active Expired
- 2002-08-13 JP JP2003521228A patent/JP4159988B2/ja not_active Expired - Lifetime
- 2002-08-13 MX MXPA04001452A patent/MXPA04001452A/es active IP Right Grant
- 2002-08-13 EA EA200400183A patent/EA006445B9/ru unknown
- 2002-08-13 ME MEP-2008-520A patent/ME00414B/me unknown
- 2002-08-13 OA OA1200400044A patent/OA12650A/en unknown
- 2002-08-13 RS YU10304A patent/RS53251B/sr unknown
- 2002-08-13 WO PCT/US2002/025649 patent/WO2003016305A1/en active IP Right Grant
- 2002-08-13 KR KR1020047002173A patent/KR100639281B1/ko active IP Right Grant
- 2002-08-13 DK DK02759342.5T patent/DK1419151T3/da active
- 2002-08-13 TR TR2019/00509T patent/TR201900509T4/tr unknown
- 2002-08-13 CN CNB2005101286242A patent/CN100364991C/zh not_active Expired - Lifetime
- 2002-08-13 NZ NZ531232A patent/NZ531232A/en not_active IP Right Cessation
- 2002-08-13 ES ES11156767.3T patent/ES2623094T3/es not_active Expired - Lifetime
- 2002-08-13 DK DK16196036.4T patent/DK3168218T3/en active
- 2002-08-13 CN CNB02815892XA patent/CN100439360C/zh not_active Expired - Lifetime
- 2002-08-13 SK SK90-2004A patent/SK902004A3/sk unknown
- 2002-08-13 EP EP02759342.5A patent/EP1419151B1/en not_active Expired - Lifetime
- 2002-08-13 UA UA2004021084A patent/UA76483C2/uk unknown
- 2002-08-13 US US10/218,985 patent/US20030069298A1/en not_active Abandoned
- 2002-08-13 GE GE5446A patent/GEP20063777B/en unknown
- 2002-08-13 PL PL368317A patent/PL216524B1/pl unknown
- 2002-08-13 CA CA002455050A patent/CA2455050C/en not_active Expired - Lifetime
- 2002-08-13 AP APAP/P/2004/002976A patent/AP1660A/en active
- 2002-08-13 PT PT2759342T patent/PT1419151E/pt unknown
- 2002-08-13 EP EP11156767.3A patent/EP2332934B1/en not_active Expired - Lifetime
- 2002-08-13 BR BR0211612-0A patent/BR0211612A/pt not_active Application Discontinuation
- 2002-08-13 HU HU0700036A patent/HU229206B1/hu unknown
- 2002-08-13 ES ES16196036T patent/ES2705063T3/es not_active Expired - Lifetime
- 2002-08-13 PT PT16196036T patent/PT3168218T/pt unknown
- 2002-08-13 IL IL16009702A patent/IL160097A0/xx active IP Right Grant
- 2002-08-13 SI SI200231043T patent/SI1419151T1/sl unknown
- 2002-08-13 CZ CZ2004196A patent/CZ2004196A3/cs unknown
- 2002-08-15 TW TW091118419A patent/TWI269796B/zh active
- 2002-08-15 MY MYPI20023032A patent/MY139383A/en unknown
- 2002-08-15 AR ARP020103088A patent/AR036261A1/es unknown
-
2004
- 2004-01-16 CO CO04002781A patent/CO5550431A2/es not_active Application Discontinuation
- 2004-01-28 ZA ZA2004/00706A patent/ZA200400706B/en unknown
- 2004-01-29 BG BG108553A patent/BG108553A/bg unknown
- 2004-02-02 HR HR20040112A patent/HRP20040112B1/xx not_active IP Right Cessation
- 2004-02-10 EC EC2004004975A patent/ECSP044975A/es unknown
- 2004-02-10 IS IS7147A patent/IS7147A/is unknown
- 2004-02-11 MA MA27522A patent/MA27058A1/fr unknown
- 2004-02-12 CU CU20040029A patent/CU23713B7/es active IP Right Grant
- 2004-02-12 TN TNP2004000028A patent/TNSN04028A1/fr unknown
- 2004-03-12 NO NO20041054A patent/NO326508B1/no not_active IP Right Cessation
- 2004-12-01 HK HK04109465.3A patent/HK1066542A1/xx not_active IP Right Cessation
-
2006
- 2006-07-28 HK HK06108404A patent/HK1088008A1/xx not_active IP Right Cessation
-
2007
- 2007-04-26 US US11/740,644 patent/US7435832B2/en not_active Expired - Lifetime
-
2018
- 2018-12-12 CY CY20181101336T patent/CY1121552T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG108553A (bg) | Кристали, включващи сол на ябълчената киселина c n-[2-(диетиламино) етил]-5-[(5-флуоро-2-оксо-3н-индол-3-илиден) метил]-2,4-диметил-1н-пирол-3-карбоксамид, методи за получаването им и техни състави | |
AU2002324684A1 (en) | Crystals including a malic acid salt of N-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3H-indole-3-ylidene) methyl]-2, 4-dimethyl-1H-pyrrole-3-carboxamide, processes for its preparation and compositions thereof | |
CA2493310C (en) | 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition | |
HUE028620T2 (en) | Tetrahydroisoquinoline derivative salt and solvates | |
KR100820511B1 (ko) | 결정성 피라졸 유도체 | |
CN113966332A (zh) | Cdk9抑制剂的多晶型物及其制法和用途 | |
US9290479B2 (en) | Solid salt forms of a pyrrole substituted 2-indolinone | |
WO2012122921A1 (zh) | 一种酪氨酸激酶抑制剂的盐形式 | |
WO2004076403A1 (en) | Sumatriptan crystalline forms, pharmaceutical compositions and methods | |
EA039764B1 (ru) | Соль n-(2,6-диэтилфенил)-8-({4-[4-(диметиламино)пиперидин-1-ил]-2-метоксифенил}амино)-1-метил-4,5-дигидро-1h-пиразоло[4,3-h]хиназолин-3-карбоксамида, ее получение и препараты, которые ее содержат |